Impact of Plasma ESR1 Mutations on Outcomes of First-Line Paclitaxel and Bevacizumab in Patients With Advanced ER+/HER2− Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
Breast Cancer Res Treat 2023 Jul 01;200(2)271-279, MK Bos, SW Lam, G Motta, JCA Helmijr, CM Beaufort, E de Jonge, JWM Martens, E Boven, MPHM Jansen, A Jager, S SleijferFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.